CALCA and migraine disorder: Literature suggests that CGRP-mAbs, along with their favorable safety and tolerability profile, might be superior compared to previously established preventive migraine therapies such as beta-blockers, antiepileptics, calcium-channel blockers, or tricyclic antidepressants: A meta-analysis comparing topiramate to CGRP-antibodies in EM confirmed the excellent tolerability of monoclonal antibodies despite a comparable reduction of migraine days [16].